VENLO, The Netherlands, May 19, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).

QIAGEN N.V. has in total received acceptances from shareholders in Exiqon A/S representing 81.37 % of the share capital and voting rights in Exiqon A/S. In accordance with the conditions of the Offer and section 9 of the Danish Takeover Order no. 562 of 2 June 2014, QIAGEN N.V. has decided to extend the Offer Period as set out in the Offer. Consequently, the Offer is valid as of 19 April 2016 and expires on  2 June 2016 at 23:59 (CET).

"We are confident that not only Exiqon's board of directors and the largest shareholders appreciate our compelling and fair offer, but also all other shareholders", commented Peer Schatz, CEO of QIAGEN N.V. "We realize that some shareholders may need more time to review the offer. We trust that in the end they will recognise that the offer values the company appropriately, and that we will reach the 90% acceptance rate necessary to complete the transaction."

Click here [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7bB8D87077-CB89-4755-B40D-D9746A9ECB2D%7d&lang=en ] for full press release 


        
         
        Contacts:

         
        Public Relations: 
        Dr. Thomas Theuringer 
        Director Public Relations 
        +49-2103-29-11826 
        Email: pr@qiagen.com 
        www.twitter.com/qiagen 
        https://www.facebook.com/QIAGEN 
        pr.qiagen.com 
        [http://www.qiagen.com/about-us/press-and-media ] 
        Investor Relations: 
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 
        Email: ir@qiagen.com 
        ir.qiagen.com [http://www.qiagen.com/about-us/investors ]  

 

SOURCE QIAGEN N.V.